Drucker commented: GLP1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing There was a hope that we would see some benefit, and we didnt. From the Alzheimers Drug Discovery Foundation (ADDF), Howard Fillit, MD, emphasized that even negative trials move the field forward, pointing to the need to target the broader pathobiology of Alzheimers and to consider preventive or combination approaches informed by biomarker profiles
Frequently Asked Questions Is it safe to take metformin and semaglutide together
Conner Mertens 19:31 Well Robert, thanks for breaking down biosimilars for us
Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S